1. Scrip
  2. >>New Products

BMS Aims To Unseat Otezla In Psoriasis With US FDA-Approved Sotyktu

TYK2 Inhibitor Grows Bristol’s Immunology Franchise

 
• By Mandy Jackson

Chief commercialization officer Chris Boerner said BMS plans to replace Otezla as the oral standard of care for moderate-to-severe psoriasis with Sotyktu (deucravacitinib); its list price is about 40% higher than Amgen’s product.

Start up concept with businessman holding briefcase and standing in front of rocket shaped gap in wall, revealing sunlit New York city view
BMS hired a whole new dermatology sales team to market Sotyktu • Source: Shutterstock

Bristol Myers Squibb Company has been preparing for a long time to launch its most recently approved product, the TYK2 inhibitor Sotyktu (deucravacitinib). And with its first dermatology drug, the company has set a big goal – to become the new standard of care for treating psoriasis with an oral therapy, unseating Amgen, Inc.’s established PDE4 inhibitor Otezla (apremilast).

The US Food and Drug Administration approved Sotyktu for the treatment of moderate-to-severe plaque psoriasis on 9 September with a label that does not include the limitations that JAK inhibitors have due to safety concerns. BMS has maintained that although TYK2 is a target within the JAK family, drugs targeting TYK2 do not have the same safety concerns, such as thrombosis

More from New Products

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

Pipeline Watch: Five Approvals And One Phase III Readout

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Merck KGaA Seals SpringWorks Buy

 
• By Kevin Grogan

The German group is paying $3.9bn to get hold of the US firm and its two approved products.

More from Scrip

BioNTech Aims To Diversify BNT323 Manufacturing As Filing Nears

 
• By Alaric DeArment

The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

 
• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.

Finance Watch: Unity Lays Off All Employees As It Evaluates Alternatives

 
• By Mandy Jackson

Restructuring Edition: Unity unveiled more Phase IIb data for lead asset UBX1325 along with plans to shed its workforce while seeking a partner for it and other drugs. Also, Ono is consolidating US employees at one site, Entrada is cutting its workforce by 20% and other recent strategic shifts.